Editorial: Advances in Chemotherapy-resistant Hepatocellular Carcinoma

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Nov 29

PMID 38020167

Authors

Shui Liu

Qiao Li

Yongzhi Li

Jiyao Sheng

Affiliations

Soon will be listed here.

References

Zeng J, Zeng J, Huang Y, Liu J, Zeng J . The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification. Hepatobiliary Pancreat Dis Int. 2022; 22(5):482-489. DOI: 10.1016/j.hbpd.2022.07.007. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Laface C, Fedele P, Maselli F, Ambrogio F, Foti C, Molinari P . Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities. Cancers (Basel). 2022; 14(16). PMC: 9406380. DOI: 10.3390/cancers14164028. View

Sanchon-Sanchez P, Briz O, Macias R, Abad M, Sanchez-Martin A, Marin J . Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs. Biomed Pharmacother. 2023; 168:115658. DOI: 10.1016/j.biopha.2023.115658. View

Sun Y, Zhang W, Bi X, Yang Z, Tang Y, Jiang L . Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements. Liver Cancer. 2022; 11(3):192-208. PMC: 9218612. DOI: 10.1159/000521596. View

Liu N, Zhang J, Chen W, Ma W, Wu T . The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression. J Exp Clin Cancer Res. 2023; 42(1):263. PMC: 10566113. DOI: 10.1186/s13046-023-02844-5. View

Kodali S, Connor A, Thabet S, Brombosz E, Ghobrial R . Liver transplantation as an alternative for the treatment of intrahepatic cholangiocarcinoma: Past, present, and future directions. Hepatobiliary Pancreat Dis Int. 2023; 23(2):129-138. DOI: 10.1016/j.hbpd.2023.07.007. View

Bridgewater J, Galle P, Khan S, Llovet J, Park J, Patel T . Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6):1268-89. DOI: 10.1016/j.jhep.2014.01.021. View

Sankar K, Gong J, Osipov A, Miles S, Kosari K, Nissen N . Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2023; 30(1):1-15. PMC: 10776289. DOI: 10.3350/cmh.2023.0125. View

10.

Pinter M, Scheiner B, Pinato D . Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol. 2023; 8(8):760-770. DOI: 10.1016/S2468-1253(23)00147-4. View

11.

Penzkofer L, Groger L, Hoppe-Lotichius M, Baumgart J, Heinrich S, Mittler J . Mixed Hepatocellular Cholangiocarcinoma: A Comparison of Survival between Mixed Tumors, Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma from a Single Center. Cancers (Basel). 2023; 15(3). PMC: 9913586. DOI: 10.3390/cancers15030639. View

12.

Leowattana W, Leowattana T, Leowattana P . Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol. 2023; 29(10):1551-1568. PMC: 10037251. DOI: 10.3748/wjg.v29.i10.1551. View

13.

Motomura K, Kuwano A, Tanaka K, Koga Y, Masumoto A, Yada M . Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. Cancers (Basel). 2023; 15(17). PMC: 10486942. DOI: 10.3390/cancers15174345. View

14.

Truty M, Vauthey J . Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol. 2010; 17(5):1219-25. PMC: 4103783. DOI: 10.1245/s10434-010-0976-5. View

15.

Tao M, Han J, Shi J, Liao H, Wen K, Wang W . Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2023; 10:1069-1083. PMC: 10348321. DOI: 10.2147/JHC.S411806. View